Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Feb 20, 2024

—CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024— —New CM-101 Patents Granted by...

Feb 14, 2024

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today...

Feb 5, 2024

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases...

Jan 30, 2024

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming...

All News

Stock Info
NASDAQCMMB
Events
Thursday, March 7, 2024
7:00am EST

A press release including financial tables and a corporate update will be issued at 7:00 am Eastern Time, Thursday, March 7, 2024.

Investors who would like to discuss the 2023 Fourth Quarter and Full Year results and corporate update may contact the company after issuance of the press release at ir@chemomab.com

Tuesday, March 12, 2024
10:40am EDT

Date: Mar. 12, 2024
Time: 10:40 am ET
Venue: Fontainebleau Hotel
Format: Live presentation
Information: LeerinkEvents@Leerink.com

All Events

Featured Presentations

Download

Chemomab Corporate Overview - February 2024

 

Annual Report

Download

Chemomab 2022 Annual Report